Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare two non-myeloablative conditioning regimens (combination of
chemotherapy and immune specific proteins against immune cells) for relapsing remitting
multiple sclerosis (RRMS). The two conditioning regimens are the most commonly used world
wide in clinical practice for the treatment of multiple sclerosis (MS). The first
investigational conditioning regimen is cyclophosphamide (chemotherapy) and rATG (rabbit
anti-thymocyte globulin, a protein against immune cells). The second investigational
conditioning regimen includes the same dose of cyclophosphamide (chemotherapy) and rituximab
(a protein against immune cells). Both cyclophosphamide and either rATG or rituximab are
given to kill immune cells that are thought to be causing MS, followed by return of one's own
previously collected blood stem cells (autologous stem cell transplant) to hasten recovery.
The goal of this study is to assess the difference of these treatments in terms of toxicity
and efficacy.